Two ROCK inhibitors (ROCKi) and two LIMKi were selected and these suppressed TGFβ-induced ECM remodeling by AF clusters in a dose-dependent manner (Fig. 3A and B). The gene discussed is TGFB1; the disease is atrial fibrillation.